Business Wire

Octapharma Activities Prominent at the Upcoming 2017 ISTH Congress in Berlin, Germany

Jaa

Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held in Berlin, Germany from 8–13 July. Octapharma is delighted to be a Platinum Sponsor of the Congress, reflecting an ongoing commitment to advancing the treatment of patients with haemophilia and von Willebrand disease (VWD).

Octapharma will play a prominent role at the ISTH Congress with activities including two sponsored scientific symposia and seven poster presentations during the scientific sessions. Abstracts of the posters will be published in the Research and Practice in Thrombosis and Haemostasis journal after the Congress.

The addition of Nuwiq®, a human cell-line derived recombinant FVIII (rFVIII) for the treatment of haemophilia A, has extended Octapharma’s established haematology portfolio of coagulation factors – wilate® (von Willebrand Factor (VWF) indicated for VWD and haemophilia A), octanate® (VWD and haemophilia A) and octanine®F (haemophilia B).

Two leading-edge symposia on new developments in bleeding management in Haemophilia A and VWD

The latest developments with Nuwiq ® , a naturally long-acting rFVIII made in human cells to protect against bleeds while addressing the risk of inhibitors in patients with haemophilia A, will be discussed in a scientific symposium, “Life without limitation: Growing experience with Nuwiq ® in patients with haemophilia A”. The symposium will be held on Sunday 9 July 2017 (16:15–17:45, Room A8). The symposium will focus on interim data from a clinical study (NuProtect) of Nuwiq® in previously untreated patients as well as clinical trial (NuPreviq) data and real-life clinical experience with the NuPreviq approach of pharmacokinetic (PK)-guided personalised prophylaxis and its potential to reduce the number of infusions and bleeding rates in patients with haemophilia A.

The latest developments with wilate ® , a high purity, double virus-inactivated VWF/FVIII concentrate containing both factors in a physiological 1:1 ratio, in VWD and haemophilia A, will be discussed in a scientific symposium, “wilate ® for a lifetime of care: Bleeding management across high-risk patient populations”. The symposium will be held on Monday 10 July 2017 (13:15–14:30, Room Paris). The symposium will focus on the treatment of high-risk patients throughout life, including patients with FVIII or VWF inhibitors, women undergoing pregnancy and delivery with VWD, and ageing VWD patients.

Seven posters presenting new data and ongoing experience across products:

Four posters on Nuwiq ® will be displayed during the Congress:

Monday 10 July, Exhibition Hall 2.2, authors present 12.00–13.15

  • Efficacy and safety of Nuwiq ® (Human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures. N. Zozulya et al., Poster PB227.
  • Inhibitor development and efficacy in previously untreated patients with severe haemophilia A treated with Nuwiq ® (Human-cl rhFVIII), a 4th generation recombinant FVIII of human origin. R. Liesner et al., Poster PB211.
  • Long-term treatment with Nuwiq ® (Human-cl rhFVIII) in previously treated children with severe haemophilia A. A. Klukowska et al., Poster PB207.
  • Pharmacokinetic guided personalised prophylaxis with Nuwiq ® (Human-cl rhFVIII) in adult patients with severe haemophilia A. C. Kessler et al., Poster PB1794.

Two posters on wilate ® will be displayed at the Congress:

Monday 10 July, Exhibition Hall 2.2, authors present 12.00–13.15

  • International clinical study investigating the incidence of inhibitors in previously untreated patients with severe haemophilia A treated with a high purity FVIII/VWF concentrate in a 1:1 ratio. T. Andreeva, et al., Poster PB238.
  • Surgeries in adults and children with von Willebrand’s disease – results from the ongoing study Wilate-STATE. S. Halimeh, et al., Poster PB383.

A poster describing the final results of a clinical trial in PUPs with haemophilia A treated with octanate ® , a human plasma-derived, high-purity, freeze-dried, double virus-inactivated FVIII concentrate, will be displayed at the Congress:

Wednesday 12 July, Exhibition Hall 2.2, authors present 12.00–13.15

  • Final results from the PUP-GCP trial: A low inhibitor rate in previously untreated patients with severe haemophilia A treated with octanate ® . A. Klukowska, et al., Poster PB1787.

Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results across our haematology portfolio and look forward to sharing our latest data at the ISTH 2017 Congress”.

Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s strong presence at the ISTH 2017 Congress reflects our ongoing commitment to improve the lives of patients with coagulation disorders.”

About Haemophilia A

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.

About von Willebrand disease

VWD is the most common of the inherited bleeding disorders, with approximately 1% of the population having VWF levels below normal. VWD is classified as type 1 (generally mild), type 2 (variable) or type 3 (severe). The symptoms of VWD are usually those of platelet dysfunction and include nose bleeds, skin bruises and haematomas, prolonged bleeds from trivial wounds, oral cavity bleeding, and excessive menstrual bleeding. Gastrointestinal bleeds are relatively rare, but may be very serious when they occur. Severe deficiency of VWF, or a specific defect in the interaction of VWF with FVIII, causes a secondary moderate deficiency of FVIII. These patients may have symptoms that are more characteristic of haemophilia, such as bleeds into joints or soft tissues including muscle and brain.

About Nuwiq ®

Nuwiq® is a natural, long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.

About wilate ®

wilate® is the first double virus inactivated VWF/FVIII, high purity concentrate, utilising the solvent/detergent (S/D) process and Permaheat - a special terminal dry heating (TDH) step. The selected purification processes isolate the VWF/FVIII complex under highly protein protecting conditions, resulting in a 1:1 ratio of VWF:RCo (ristocetin cofactor) to FVIII activity that is similar to normal plasma. No albumin is added as a stabiliser. wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres. wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma. The product is registered in more than 60 countries worldwide, including most EU countries, the US, Canada, Australia, Brazil and Russia.

About octanate ®

octanate® is a human plasma-derived, high-purity, freeze-dried, double virus-inactivated FVIII concentrate for intravenous administration. Coagulation FVIII present in octanate® is bound to its natural stabiliser, von Willebrand factor (VWF), in a VWF/FVIII ratio of approximately 0.4. Therefore, no additional stabilisers are required during manufacturing.

octanate® is used in the prophylaxis and treatment of bleeding in patients with all types of haemophilia A. octanate® is available in 250 IU, 500 IU and 1000 IU presentations. octanate® was first launched in Germany in 1998 and has since been approved in 86 countries. Since its launch, a total of approximately 10 billion IU octanate® have been distributed worldwide. octanate ® is indicated for immune tolerance induction (ITI) in over 40 countries.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:

· Haematology (coagulation disorders)

· Immunotherapy (immune disorders)

· Critical care

Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

Contact information

Octapharma AG
International Business Unit- Haematology
Olaf Walter
Olaf.Walter@octapharma.com
or
Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GTIS Partners Clinches Sustainability Performance Top Honors for Third Year Running20.9.2017 16:32Tiedote

GTIS Partners LP (“GTIS”), a real estate private equity firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris and Munich, today announced that the GTIS Brazil Real Estate Fund I has been recognized as 2017’s most sustainable private equity real estate investment fund in South America by the Global Real Estate Sustainability Benchmark (GRESB). This is the third year in a row that the fund has taken top honors. In addition, GRESB awarded GTIS Brazil Real Estate Fund II first place in the specialized category of non-listed real estate funds with hotel concentrations, and a number two ranking overall. GTIS Brazil Real Estate Fund III, which held its final closing in December 2016 with approximately $680 million in commitments, took third place. “GTIS Partners received another top honor with the #1 rank for South America in the

The Meet Group to Acquire LOVOO20.9.2017 15:31Tiedote

The Meet Group, Inc. (NASDAQ:MEET), a public market leader in the mobile meeting space, today announced it has executed a definitive agreement to acquire LOVOO, a social dating app, for $70 million in cash, inclusive of a $5 million contingent earn-out. This acquisition furthers The Meet Group’s strategy to innovate, acquire, and build the largest mobile portfolio of brands for meeting new people. The LOVOO acquisition is expected to expand The Meet Group’s global footprint, increase the company’s scale and profitability, and diversify its business model by adding expertise in subscription and in-app purchasing. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005645/en/ LOVOO is a social and mobile technology company based in Germany: The #1 Dating App in German speaking countries (Ger

Arthur D. Little Urges Network Operators to Prepare for Next-Generation Internet of the GigaWorld20.9.2017 14:00Tiedote

In its new report, “Unlocking GigaWorld Innovation: GigaApps in a GigaWorld,” Arthur D. Little (ADL) outlines the investment and monetization opportunities available to network operators ready to embrace the “GigaWorld”, the emerging third cycle of the internet. Defined by continuous and intelligent collaboration between individuals, devices and the built environment – and driven by applications in the areas of augmented reality, virtual telepresence and automated living – the GigaWorld has the potential to both power our economy and change the way we live. However, for it to be fully realized, network operators need to deliver improved Quality of Experience (QoE) for consumers and new Quality of Service (QoS) features for content and service providers. While operators have focused on delivering sufficient bandwidth and coverage to drive the current iteration of the internet, the GigaWorld

LINTEC Announces Four New Adhesive Materials for Labels20.9.2017 13:45Tiedote

LINTEC Corporation (TOKYO: 7966) announced on September 20 that it will launch four newly developed label adhesive materials sequentially from October 2017. The new products will be on display prior to launch at Labelexpo Europe 2017, the world’s largest trade show in the label field. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005611/en/ LINTEC's super-strength adhesive labelstocks (Photo: Business Wire) Overview of Labelexpo Europe 2017 Date: September 25 (Mon.) to 28 (Thurs.) Venue: Brussels Expo, Belgium LINTEC Booth: Hall 3 3C 15 LINTEC Press Conference: 11:00 a.m. to 11:30 a.m., September 25, held in the Brussels Expo Press Office Theater Super-strength adhesive labelstocks: Extreme adhesion for rough surfaces Charac

EGS Invests in Artificial Intelligence from Quintiq20.9.2017 13:05Tiedote

Quintiq, a Dassault Systèmes brand and global leader in supply chain planning and optimization (SCP&O), announces that it has partnered with European Gateway Services (EGS) to bring a new level of intelligence to intermodal logistics. European Gateway Services (EGS) offers the market an integrated network for transport to and from the European hinterland. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005578/en/ EGS invests in artificial intelligence from Quintiq (Photo: Business Wire) To better support its customers, EGS takes standard planning strategies to a new level with a synchromodal trip optimizer using Quintiq’s planning and optimization software, which employs artificial intelligence to choose the optimal modes and routes at all times. Quintiq technology makes s

EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch20.9.2017 12:03Tiedote

SES, EchoStar Corp., and Airbus Defence and Space announced today that the new EchoStar 105/SES-11 spacecraft, built by Airbus, has been shipped from the Airbus facilities in Toulouse, France, to Cape Canaveral, Florida, for its forthcoming launch by SpaceX in October. The first satellite that EchoStar has constructed with manufacturer Airbus, EchoStar 105/SES-11 will be launched by SpaceX on a flight-proven Falcon 9 rocket from Launch Complex 39A at Kennedy Space Center, Florida. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005539/en/ EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch (Photo: Business Wire) EchoStar 105/SES-11, a high-powered hybrid Ku and C-band communications satellite, is a dual-mission satellite for US-based operator EchoStar and Luxembourg-based

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme